International Harmonization of Regulation of Nanomedicine

G. Marchant, Douglas J. Sylvester, Kenneth W. Abbott, T. Danforth
{"title":"International Harmonization of Regulation of Nanomedicine","authors":"G. Marchant, Douglas J. Sylvester, Kenneth W. Abbott, T. Danforth","doi":"10.2202/1941-6008.1120","DOIUrl":null,"url":null,"abstract":"Nanomedicine holds enormous promise for the improved prevention, detection and treatment of disease. Yet, at the same time, countervailing concerns about the potential safety risks of nano-technologies generally, and nanomedical products specifically, threaten to derail or at least delay the introduction and commercial viability of many nanomedicine applications. All around the globe, national governments are struggling with balancing these competing benefits and risks of nanotechnology in the medical and other sectors. It is becoming increasingly clear that reasonable, effective and predictable regulatory structures will be critical to the successful implementation of nanotechnology. The question examined in this paper is whether there are mechanisms of international harmonization or cooperation that can facilitate the development of more effective and efficient regulatory regimes for nanomedicine?Part I of this paper briefly summarizes the promise of nanomedicine as well as potential concerns about the risks of nanomedical applications that will require regulatory oversight. In Part II, we analyze the various factors weighing for and against attempts to harmonize regulatory requirements at the international level. Finally, in Part III we identify some specific existing or feasible mechanisms that may be useful for fostering international harmonization in the regulation of nanomedicine.","PeriodicalId":88318,"journal":{"name":"Studies in ethics, law, and technology","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2010-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2202/1941-6008.1120","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Studies in ethics, law, and technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2202/1941-6008.1120","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

Abstract

Nanomedicine holds enormous promise for the improved prevention, detection and treatment of disease. Yet, at the same time, countervailing concerns about the potential safety risks of nano-technologies generally, and nanomedical products specifically, threaten to derail or at least delay the introduction and commercial viability of many nanomedicine applications. All around the globe, national governments are struggling with balancing these competing benefits and risks of nanotechnology in the medical and other sectors. It is becoming increasingly clear that reasonable, effective and predictable regulatory structures will be critical to the successful implementation of nanotechnology. The question examined in this paper is whether there are mechanisms of international harmonization or cooperation that can facilitate the development of more effective and efficient regulatory regimes for nanomedicine?Part I of this paper briefly summarizes the promise of nanomedicine as well as potential concerns about the risks of nanomedical applications that will require regulatory oversight. In Part II, we analyze the various factors weighing for and against attempts to harmonize regulatory requirements at the international level. Finally, in Part III we identify some specific existing or feasible mechanisms that may be useful for fostering international harmonization in the regulation of nanomedicine.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
国际纳米医学监管协调
纳米医学在改善疾病的预防、检测和治疗方面有着巨大的希望。然而,与此同时,对纳米技术的潜在安全风险,特别是纳米医学产品的潜在安全风险的反补贴担忧,有可能破坏或至少推迟许多纳米医学应用的引入和商业可行性。在全球范围内,各国政府都在努力平衡纳米技术在医疗和其他领域的竞争利益和风险。越来越清楚的是,合理、有效和可预测的管理结构对于纳米技术的成功实施至关重要。本文审查的问题是,是否存在国际协调或合作机制,可以促进发展更有效和高效的纳米医学管理制度?本文的第一部分简要总结了纳米医学的前景以及纳米医学应用的潜在风险,这些风险将需要监管监督。在第二部分中,我们分析了在国际层面协调监管要求的各种因素。最后,在第三部分中,我们确定了一些具体的现有或可行的机制,这些机制可能有助于促进纳米医学监管的国际协调。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Political Legitimacy Review of Reframing Rights: Bioconstitutionalism in the Genetic Age Review of Interfaces on Trial 2.0 From ICH to IBH in Biobanking? A Legal Perspective on Harmonization, Standardization and Unification The Price of Precaution and the Ethics of Risk
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1